Caring Brands, Inc. (NASDAQ:CABR) Short Interest Down 45.7% in April

Caring Brands, Inc. (NASDAQ:CABR) was the recipient of a large decline in short interest in the month of April. As of April 30th, there was short interest totaling 18,964 shares, a decline of 45.7% from the April 15th total of 34,917 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average daily volume of 53,861 shares, the days-to-cover ratio is currently 0.4 days.

Caring Brands Stock Down 4.1%

CABR traded down $0.04 during trading hours on Friday, reaching $0.94. 118,400 shares of the company’s stock traded hands, compared to its average volume of 73,406. The company’s 50-day moving average price is $1.04. Caring Brands has a 52-week low of $0.71 and a 52-week high of $5.35. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.66 and a quick ratio of 13.09. The firm has a market capitalization of $8.55 million and a price-to-earnings ratio of -2.54.

Caring Brands (NASDAQ:CABR) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Caring Brands

A hedge fund recently bought a new stake in Caring Brands stock. Jane Street Group LLC bought a new stake in shares of Caring Brands, Inc. (NASDAQ:CABR) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands as of its most recent SEC filing.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings began coverage on Caring Brands in a report on Monday, January 26th. They issued a “sell (e)” rating for the company. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.